The Early Access and the Potential Cost Savings by the Compassionate Use of Onco-haematological Drugs: Results from the Italian Study Compass-O.
Irene Dell'AnnoLeonardo DondiImmacolata EspositoAnnamaria MascoloAnnalisa CapuanoGiulia de MarchiAdriano CristinzianoDomenico TarantinoMarcello PaniCarla MasiniCaterina DonatiElisabetta RossinAntonio SerafiniGabriele BagagliniGabriella BonanniTommaso GregoriArturo CavaliereRoberta MatocciAlessandro D'ArpinoNello MartiniCarlo PiccinniPublished in: Clinical drug investigation (2024)
The study Compass-O showed a significant economic burden of CDU and a relevant need for early access, particularly for innovative drugs. However, there is currently no structured monitoring of CDU in Italy, suggesting the need for a national observatory, of which Compass-O can be the pilot phase.